Lisanti Capital Growth’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.71M Sell
38,612
-5,130
-12% -$1.01M 1.94% 8
2025
Q4
$8.27M Buy
43,742
+14,065
+47% +$2.7M 1.96% 3
2025
Q3
$5.26M Buy
29,677
+19,002
+178% +$2.82M 1.29% 30
2025
Q2
$1.21M Sell
10,675
-41,900
-80% -$4.48M 0.34% 90
2025
Q1
$5.53M Buy
52,575
+13,565
+35% +$1.53M 1.64% 13
2024
Q4
$4.18M Buy
39,010
+14,225
+57% +$1.61M 1.01% 42
2024
Q3
$2.48M Buy
+24,785
New +$2.5M 0.63% 70
2019
Q1
Sell
-17,601
Closed -$1.49M 124
2018
Q4
$1.49M Sell
17,601
-8,496
-33% -$906K 0.6% 67
2018
Q3
$4.47M Buy
26,097
+3,166
+14% +$477K 1.55% 16
2018
Q2
$2.96M Buy
22,931
+1,555
+7% +$174K 1.13% 34
2018
Q1
$2.2M Buy
+21,376
New +$2.11M 1.06% 40
2016
Q3
Sell
-11,421
Closed -$850K 102
2016
Q2
$850K Sell
11,421
-2,237
-16% -$166K 1.28% 29
2016
Q1
$912K Buy
13,658
+10,204
+295% +$620K 1.08% 40
2015
Q4
$234K Buy
+3,454
New +$213K 0.25% 88
2014
Q2
Sell
-52,394
Closed -$2.2M 105
2014
Q1
$2.2M Buy
52,394
+19,893
+61% +$829K 0.95% 56
2013
Q4
$1.07M Buy
+32,501
New +$1.06M 0.45% 82
2013
Q3
Sell
-40,388
Closed -$1.19M 105
2013
Q2
$1.19M Buy
+40,388
New +$726K 0.57% 69

Other funds holding LGND

Lisanti Capital Growth's LGND Position: Q1 2026 in Review

Lisanti Capital Growth reduced its Ligand Pharmaceuticals (LGND) stake by 12% in Q1 2026, selling an estimated $1.01M and leaving 38,612 shares worth $7.71M. The position accounts for 1.94% of the portfolio, ranked #8.

Lisanti Capital Growth first reported a position in LGND in Q2 2013 and has held it in 17 quarters since. The position peaked at $8.27M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Lisanti Capital Growth held 38,612 shares of Ligand Pharmaceuticals worth $7.71M as of Q1 2026.
  • Lisanti Capital Growth sold 5,130 Ligand Pharmaceuticals shares in Q1 2026, an estimated $1.01M.
  • Ligand Pharmaceuticals made up 1.94% of Lisanti Capital Growth's portfolio in Q1 2026, its #8 holding.
  • Lisanti Capital Growth first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • Lisanti Capital Growth's Ligand Pharmaceuticals position peaked at $8.27M in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.